Study of Investigational Drug in Osteoporosis

This study has been completed.

First Received: September 21, 2004 Last Updated: January 21, 2010 History of Changes

Sponsor:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00092053

Purpose

The purpose of this study is to evaluate the efficacy and safety of an investigational drug in postmenopausal women with osteoporosis.

Condition	Intervention	Phase
Postmenopausal Osteoporosis	Drug: MK0217, alendronate sodium/Duration of Treatment: 3 months Drug: Comparator: placebo / Duration of Treatment: 3 months	Phase III

Study Type:	Interventional
Study Design:	Randomized, Double Blind (Subject, Investigator), Safety/Efficacy Study
Official Title:	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Persistence of the Effect of Oral Monthly Ibandronate on Bone Reception in Postmenopausal Women in Osteoporosis

Resource links provided by NLM:

MedlinePlus related topics: Osteoporosis

Drug Information available for: Alendronate Alendronate sodium Fosamax

Further study details as provided by Merck:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	180
Study Start Date:	January 2005
Primary Completion Date:	July 2005 (Final data collection date for primary outcome measure)

Eligibility

Criteria

Inclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00092053

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

No publications provided

Responsible Party:	Merck Sharp & Dohme Corp ( Executive Vice President, Clinical and Quantitative Sciences )
Study ID Numbers:	2004_007, MK0217-908
Study First Received:	September 21, 2004
Last Updated:	January 21, 2010
ClinicalTrials.gov Identifier:	NCT00092053 History of Changes
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Merck:

Postmenopausal
Osteoporosis

Additional relevant MeSH terms:

Musculoskeletal Diseases
Alendronate
Physiological Effects of Drugs
Osteoporosis, Postmenopausal
Osteoporosis

Bone Density Conservation Agents
Bone Diseases, Metabolic
Bone Diseases
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010